Table 5.
Women Within Each BMI Group Who Were on Treatment Before and After Fracture
| Underweight (1) | Non-obese (2) | Obese (3) | Significant P values | |
|---|---|---|---|---|
| AOM use | ||||
| Before fracture | 51.5 (39.6-63.3) | 40.6 (38.7-42.5) | 27.9 (24.7-31.2) | (1) vs. (3)b, (2) vs. (3)b |
| After fracture | 63.2 (51.8-74.7) | 46.3 (44.4-48.2) | 33.2 (29.8-36.6) | (1) vs. (3)b, (2) vs. (3)b, (1) vs. (2)a |
| Calcium & vitamin D | ||||
| Before fracture | 34.9 (24.7-45.2) | 39.9 (38.1-41.6) | 38.6 (35.4-41.8) | |
| After fracture | 45.8 (35.1-56.5) | 45.2 (43.4-46.9) | 45.5 (42.2-48.7) | |
| AOM, calcium & vitamin D | ||||
| Before fracture | 26.6 (15.7-37.4) | 22.2 (20.6-23.8) | 15.8 (13.1-18.4) | (2) vs. (3)b |
| After fracture | 34.4 (22.7-46.0) | 26.0 (24.3-27.7) | 20.9 (17.9-23.9) | (1) vs. (3)a, (2) vs. (3)a |
Data are unadjusted percentages (95% confidence intervals)
AOM anti-osteoporosis medication, BMI body mass index
a
Alpha level ≤ 0.017 for pair-wise unadjusted comparisons
b
Alpha level ≤ 0.017 for pair-wise unadjusted and adjustedc comparisons
c
Adjusted for age, comorbidities (hypertension, heart disease, high cholesterol, asthma, emphysema, osteoarthritis and diabetes), and fracture type (clavicle, upper arm, wrist, spine, rib, hip, pelvis, ankle, upper and lower leg)